Our work at IMCA-CAT and HWI seeks to accelerate drug discovery research by developing and operating a state-of-the-art, industry-funded structural biology synchrotron beamline optimized for high-throughput macromolecular crystallography serving the pharmaceutical industry.
Our Research Group→
IMCA-CAT is a structural biology research facility for pharmaceutical drug discovery programs. It was established in 1992 to design, build, and operate a research facility at the Advanced Photon Source, a high energy synchrotron X-ray source at Argonne National Laboratory. Today, IMCA-CAT operates a state-of-the-art insertion device beamline for confidential and proprietary macromolecular crystallography experiments. To meet the demands of the pharmaceutical industry, IMCA-CAT is optimized for high-throughput data acquisition, is committed to generating the highest quality X-ray diffraction data, provides reliable access for proprietary research, ensures maximum efficiency, and invests in the facility to remain at the technical forefront for pharmaceutical research in structural biology.
Pharmaceutical drug discovery at the IMCA-CAT Advanced Photon Source user facility
Anne M Mulichak, Kevin Battaile, Joe Digilio, Lisa J. Keefe,
ACA. 2015 August 15; doi:10.1107/S2053273315096114
Spectral X-Ray Diffraction using a 6 Megapixel Photon Counting Array Detector
Ryan D. Muir, Nicholas R. Pogranichniy, Garth J. Simpson, J. Lewis Muir,
Proceedings of SPIE - The International Society for Optical Engineering 2015 March; doi:10.1117/12.2079548
Linear fitting of multi-threshold counting data with a pixel-array detector for spectral X-ray imaging
Ryan D Muir, Nicholas R Pogranichniy, Garth J Simpson, J Lewis Muir
Journal of Synchrotron Radiation 2014 September
The α aneurism: A structural motif revealed in an insertion mutant of staphylococcal nuclease
Lisa J. Keefe, D Shortle, J Sondek, Eaton E Lattman
Proceedings of the National Academy of Sciences. 1993 May; doi: 10.1073/pnas.90.8.3275